Cardiff Oncology Q2 2026: positive Phase 2 mCRC data, FDA aligned on Phase 3, licensing dispute

Cardiff Oncology, Inc.

2026-Q2 EPS reported -$0.32 revenue$145,000

Q2 2026 cash ~$34.5M; six-month net cash burn $24.1M vs $21.1M in 2025; runway into Q3 2027
Phase 2 CRDF-004: 30mg onvansertib+FOLFIRI/bev confirmed ORR 72.2% vs 42.1% for SoC; PFS HR 0.55 (BICR)
Completed FDA End-of-Phase 2 meeting; aligned on Phase 3 design; initiation planned Q1 2027 subject to financing
Completed $10M registered direct offering in July 2026 to extend cash runway
Licensor NMS alleged material breach and terminated license; Cardiff filed lawsuit in May 2026 seeking declaratory relief

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.